非酒精性脂肪性肝病高危人群:监测与防治

doi:10.3969/j.issn.1672-5069.2020.05.002

Abstract

Li Junying, Zhou Ling, Chen Jinjun. Surveillance and management of individuals with high risk of NAFLD[J]. Journal of Practical Hepatology, 2020, 23(5): 612-614.

[1] CarlssonB, Lindén D, Brolén G, et al. The emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther, 2020,51(12):1305-1320.
[2] AlexanderM, Loomis AK, Lei J, et al. Non-alcoholic fatty liver disease and risk of incident acute myocardial infarction and stroke: findings from matched cohort study of 18 million European adults. BMJ, 2019,367:l5367.
[3] Lonardo A, Bellentani S, KArgo C, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: focus on high-risk groups. Dig Liver Dis, 2015,47(12):997-1006.
[4] Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol, 2015,13(4):643-654.
[5] Cowman S. Commentary on forensic and non-forensic psychiatric nursing skills and competencies for psychopathic and personality disordered patients. J Clin Nurs, 2014,23(7-8):1170-1171.
[6] Lebeau PF, Byun JH, Platko K, et al. Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice. JHEP Rep, 2019, 1(6):418-429.
[7] Younossi ZM, Golabi P, de Avila L, et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis.J Hepatol, 2019,71(4):793-801.
[8] Chang Y, Cho YK, Kim Y, et al. Nonheavy drinking and worsening of noninvasive fibrosis markers in nonalcoholic fatty liver disease: a cohort study. Hepatology, 2019,69(1):64-75.
[9] Bhanji RA, Narayanan P, Allen AM, et al. Sarcopenia in hiding: the risk and consequence of underestimating muscle dysfunction in nonalcoholic steatohepatitis. Hepatology, 2017,66(6):2055-2065.
[10] Kim JA, Choi KM. Sarcopenia and fatty liver disease. Hepatol Int, 2019,13(6):674-687.
[11] Barata L, Feitosa MF, Bielak LF, et al. Insulin resistance exacerbates genetic predisposition to nonalcoholic fatty liver disease in individuals without diabetes. Hepatol Commun, 2019,3(7):894-907.
[12] Xia MF, Chen LY, Wu L, et al. The PNPLA3 rs738409 C>G variant influences the association between low skeletal muscle mass and NAFLD: The Shanghai Changfeng study. Aliment Pharmacol Ther, 2019,50(6):684-695.
[13] Zelber-Sagi S, Lotan R, Shlomai A, et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol, 2012,56(5):1145-1151.
[14] Koo BK, Joo SK, Kim D, et al. Additive effects of PNPLA3 and TM6SF2 on the histological severity of non-alcoholic fatty liver disease. J Gastroenterol Hepatol, 2018,33(6):1277-1285.
[15] Turati F, Talamini R, Pelucchi C, et al. Metabolic syndrome and hepatocellular carcinoma risk. Br J Cancer, 2013,108:222-228.
[16] Estes C, Anstee QM, Arias-Loste MT, et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for theperiod 2016-2030. J Hepatol, 2018,69(4):896-904.
[17] Hannah WN Jr, Harrison SA. Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatology, 2016,64(6):2234-2243.
[18] Yoneda M, Imajo K, Takahashi H, et al. Clinical strategy of diagnosing and following patients with nonalcoholic fatty liver disease based on invasive and noninvasive methods.J Gastroenterol. 2018,53(2):181-196.
[19] 李俊缨,熊鸣,张继平,等.非酒精性脂肪性肝炎相关肝硬化的诊断和治疗进展. 肝脏. 2019,24(10):1008-1704.
[20] Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology, 2011,53:1020-1022.
[21] Goldner D, Lavine JE. NAFLD in children: unique considerations and challenges. Gastroenterology, 2020,158(7):1967-1983.
[22] Zelber-Sagi S, Lotan R, Shlomai A, et al. Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol, 2012,56:1145-1151.
[23] Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med, 2017,377(21):2063-2072.
[24] Vilar-Gomez E, Calzadilla-Bertot L, Wai-Sun Wong V, et al. Type 2 diabetes and metformin use associate with outcomes of patients with non-alcoholic steatohepatitis-related, Child-Pugh A cirrhosis. Clin Gastroenterol Hepatol, 2020,S1542-3565(20)30633-30639.
[25] Margini C, Dufour JF. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment. Liver Int, 2016,36:317-324.
[26] Wong VW, Chan RS, Wong GL, et al. Community-based lifestyle modification programme for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol, 2013,59:536-542.
[27] Weiss CR, Abiola GO, Fischman AM, et al. Bariatric embolization of arteries for the treatment of obesity (BEAT obesity) trial: results at 1 Year.Radiology, 2019,291(3):792-800.

Surveillance and management of individuals with high risk of NAFLD

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Hou Guanghua, Hu Qijiang, Xu Meihua , et al. Short-term efficacy of polyene phosphatidylcholine combined with metformin and fenofibrate in patients with NAFLD [J]. Journal of Practical Hepatology, 2020, 23(4): 528-531.
[2]	Liu Jian, Zhu Fengfa, Tang Juan. Ultrasonographic and biochemical features of patients with non-alcoholic heterogeneous fatty liver [J]. Journal of Practical Hepatology, 2020, 23(1): 42-45.
[3]	Wei Zhongcao, Liu Na, Xing Xin, et al. Efficacy and safety ofpolyene phosphatidylcholine combined with metformin in the treatment of patients with non-alcoholic fatty liver disease: a Meta-analysis [J]. Journal of Practical Hepatology, 2020, 23(1): 46-49.
[4]	Guo Hualei, Bu Lilin, Pei Ying, et al. Effect of Chinese herbal medicine on serum TNF-α and leptin levels in rats with NAFLD [J]. Journal of Practical Hepatology, 2020, 23(1): 138-141.
[5]	Cui Qinghua, Tao Hong, Wang Xiaoyue, et al.. Changes of serum glycosylated hemoglobin level and cardiac functions in patients with non-alcoholic fatty liver disease [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 69-72.
[6]	Dong Xuelian, Zhang Wenjun.. Application of controlled attenuation parameter in screening individuals with risk of metabolic syndrome [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(6): 868-871.
[7]	Guo Zhengning.. Contrast-enhanced ultrasound monitoring in early diagnosis of patients with small primary liver cancer [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(5): 741-744.
[8]	Liu Yanghe, Long Dengyi, Bei Zheng, et al. Efficacy of bacillus subtilis duplex and polyene phosphatidylcholine combination in treatments of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(4): 573-576.
[9]	Yang Huimin, Jiang Chunyan. Clinical efficacy of herbal medicine and silibinin in the treatment of patients with nonalcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2018, 21(3): 467-468.
[10]	Yu Hongyan, Di Fusheng. Endocrinologists should pay attention to the outcome of liver diseases in patients with diabetes and non-alcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(3): 267-270.
[11]	Zhao Wenxia，Zhang Lihui.. Application of Chinese traditional medicine in the treatment of patients with non-alcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2017, 20(2): 132-134.
[12]	Zhu Chanyan,Qu Jichen,Cao Haixia,et al.. Incidence of metabolic syndrome and non-alcoholic fatty liver diseases in patients with different histological types of lung cancer [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(3): 288-291.
[13]	Zhong Bihui. Appropriate application of lipid-regulating agents in patients with non-alcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(2): 143-146.
[14]	Yan Jinsong, Yuan Dan, Li Dongsheng. Risk factors of non-alcoholic fatty liver in patients with diabetes type two [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(2): 212-213.
[15]	Yang Shuo, Lyu Dong, Wang Tianyi, Zhang Longyou, Xu Youqing. Diagnostic efficacy of FibroTouchR by measuring fat attenuation index in detecting liver steatosis in patients with non-alcoholic fatty liver diseases [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(1): 50-54.